The Gulf Cooperation Council (GCC) region is experiencing significant economic growth including in the healthcare sector, making it a region of interest for pharma and biotech companies. Market leader, Saudi Arabia, has one of the largest pharmaceutical valuations in the region and is projected to reach $7.04 billion by 2028. Growth in the market is heavily driven by national investment in healthcare from the Saudi Arabian government as well as Saudi Arabian institutions that actively invest in healthcare and pharmaceuticals outside of the country through collaborations and seed investments.
